Role of pulmonary microorganisms in the development of chronic obstructive pulmonary disease

Liu, Jiexing; Ran, Zhuonan; Wang, Fen; Xin, Caiyan; Xiong, Bin; Song, Zhimin

doi:10.1080/1040841x.2020.1830748

Cited by 27 publications

(18 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, antibacterial drugs have potential antifungal value due to their good antifungal activity. However, human health is based on the balance of microbiota (Limon et al 2017 ; Liu et al 2020 ). If antibacterial drugs are approved for the treatment of invasive fungal infections, many problems still need to be considered.…”

Section: Antibacterial Drugsmentioning

confidence: 99%

Drug repurposing strategies in the development of potential antifungal agents

Zhang

Liu

Zeng

et al. 2021

Appl Microbiol Biotechnol

Self Cite

View full text Add to dashboard Cite

The morbidity and mortality caused by invasive fungal infections are increasing across the globe due to developments in transplant surgery, the use of immunosuppressive agents, and the emergence of drug-resistant fungal strains, which has led to a challenge in terms of treatment due to the limitations of three classes of drugs. Hence, it is imperative to establish effective strategies to identify and design new antifungal drugs. Drug repurposing is a potential way of expanding the application of existing drugs. Recently, various existing drugs have been shown to be useful in the prevention and treatment of invasive fungi. In this review, we summarize the currently used antifungal agents. In addition, the most up-to-date information on the effectiveness of existing drugs with antifungal activity is discussed. Moreover, the antifungal mechanisms of existing drugs are highlighted. These data will provide valuable knowledge to stimulate further investigation and clinical application in this field. Key points • Conventional antifungal agents have limitations due to the occurrence of drug-resistant strains. • Non-antifungal drugs act as antifungal agents in various ways toward different targets. • Non-antifungal drugs with antifungal activity are demonstrated as effective antifungal strategies.

show abstract

Section: Antibacterial Drugsmentioning

confidence: 99%

Drug repurposing strategies in the development of potential antifungal agents

Zhang

Liu

Zeng

et al. 2021

Appl Microbiol Biotechnol

Self Cite

View full text Add to dashboard Cite

show abstract

“…This impact leads to changes in patients’ antibiotic sensitivity, pulmonary immunomodulatory capacity, and pathological conditions, which further influence the disease progression [ 19 , 20 ]. In chronic obstructive pulmonary disease (COPD), decreased abundances of Firmicutes and Proteobacteria have been reported [ 21 , 22 , 23 ]. With disease progression, nCFB can also gradually become complicated with COPD, which may contribute to the changes in pulmonary microecology in nCFB patients as well as nCFB patients’ progressive decline of pulmonary function.…”

Section: Discussionmentioning

confidence: 99%

Informatic analysis of the pulmonary microecology in non-cystic fibrosis bronchiectasis at three different stages

Wang

Chen

et al. 2022

Open Life Sciences

View full text Add to dashboard Cite

This study explored the impact of pulmonary microecological changes on disease progression in non-cystic fibrosis bronchiectasis (nCFB). A careful search of the NCBI BioProject database revealed the 16S rRNA-based microbiological testing results of 441 pulmonary sputum samples from patients in the relatively stable (baseline), acute exacerbation, or recovery stage. After preliminary analysis and screening, we selected 152 samples for further analyses, including determination of the operational taxonomic unit (OTU) distribution at the phylum, class, order, family and genus levels, community structure, alpha diversity, beta diversity, microbial multivariables, correlations, and community structure after the abundances of intragroup samples were averaged. The recovery group showed significant differences in pulmonary microbiological changes (P < 0.05) compared with the other groups. There were 30 differentially abundant OTUs, with 27 and 7 at the genus and phylum levels, respectively. The Chao1 value of the recovery group was comparable to that of the baseline group, and the Shannon and Simpson values of the recovery group were the highest. Rhodococcus in Actinobacteria was positively correlated with Ochrobactrum in Firmicutes. The differences in pulmonary microecological changes at different nCFB stages may serve as a biologically predictive indicator of nCFB progression.

show abstract

“…Respiratory mucosal surfaces are colonized by a community of commensal bacteria and are also the primary site of entry for pathogenic agents [31] . Mucosal B cells release large amounts of immunoglobulin (Ig) molecules via both follicular and extrafollicular routes to prevent microbial invasion [32] .…”

Section: Discussionmentioning

confidence: 99%

Yifei Sanjie Formula Treats Chronic Obstructive Pulmonary Disease by Regulating Lung Microbiota Dysbiosis

Qiao

Zhang

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundChronic obstructive pulmonary disease (COPD) is one of the most common pulmonary diseases. There is evidence to suggest that dysbiosis of pulmonary microbiota participates in COPD development. Yifei Sanjie Formula (YS) is widely used to treat diseases in respiratory systems, yet its mechanisms are little known. MethodsIn the present study, the efficacy of YS was evaluated by analyzing its effects on the severity of pulmonary pathological damage, pulmonary function, pro-inflammation cytokines, the activation of NLRP3/caspase-1/IL-1β signaling pathway, and changes of lung microbiota. ResultsYS improved animal behaviors, prevented declines in pulmonary ventilatory function and lung injury in a rat model of COPD. Administration of YS significantly suppressed the release of proinflammatory cytokines and collagen deposition and downregulated NLRP3/caspase-1/IL-1β signaling in vivo. YS changed the relative abundance of specific pulmonary microbiota and modulated bacterial flora in the rat model. ConclusionsThese results suggest that the effects of YS involved lung microbes and anti-inflammatory mechanisms.

show abstract

Role of pulmonary microorganisms in the development of chronic obstructive pulmonary disease

Cited by 27 publications

References 94 publications

Drug repurposing strategies in the development of potential antifungal agents

Drug repurposing strategies in the development of potential antifungal agents

Informatic analysis of the pulmonary microecology in non-cystic fibrosis bronchiectasis at three different stages

Yifei Sanjie Formula Treats Chronic Obstructive Pulmonary Disease by Regulating Lung Microbiota Dysbiosis

Contact Info

Product

Resources

About